Actiq Paragraph IV Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDAs with Paragraph IV certifications for Cephalon's Actiq lozenges 0.4 mg and 0.2 mg were filed Oct. 6 and Oct. 29, respectively, FDA said in its Dec. 16 updated list of Paragraph IV filings
You may also be interested in...
Cephalon/Cima Merger Contingent On Granting Generic Actiq License To Barr
Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.